SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-270951"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-270951" > The Risk of Distant...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004794naa a2200469 4500
001oai:DiVA.org:uu-270951
003SwePub
008160105s2015 | |||||||||||000 ||eng|
009oai:portal.research.lu.se:publications/62d7ecdb-8a6c-4dbd-8add-f2b34e1535f2
009oai:swepub.ki.se:511909
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2709512 URI
0247 a https://doi.org/10.1016/j.juro.2015.07.0822 DOI
0247 a oai:portal.research.lu.se:publications/62d7ecdb-8a6c-4dbd-8add-f2b34e1535f22 URI
0247 a https://ki.se/en/research/search-research-information?t=2&query=id%3A5119092 URI
040 a (SwePub)uud (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Stattin, Karlu Uppsala universitet,Ortopedi,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)karst605
2451 0a The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml
264 1b Ovid Technologies (Wolters Kluwer Health),c 2015
338 a print2 rdacarrier
520 a Purpose: Current EAU (European Association of Urology) guidelines state that prostate specific antigen 100 ng/ml or greater at diagnosis indicates metastatic disease. We examined the association of prostate specific antigen 100 ng/ml or greater at diagnosis with distant metastasis and prostate cancer specific survival. Material and Methods: A total of 15,635 men with prostate cancer diagnosed between 1998 and 2009 who were identified in PCBaSe (Prostate Cancer Data Base Sweden 2.0) were included in a population based registry study. Prostate cancer specific survival was compared among 3 groups, including 1,879 men with prostate specific antigen 100 ng/ml or greater and negative imaging (MO), 5,642 with distant metastases on imaging (M1) and prostate specific antigen 100 ng/ml or greater, and 3,828 with M1 and prostate specific antigen less than 100 ng/ml. A fourth group consisted of 4,286 men with prostate specific antigen 100 ng/ml or greater who had not undergone imaging (Mx). The latter men were not included in the assessment of survival. Results: Of 7,521 men with prostate specific antigen 100 ng/ml or greater who underwent imaging for staging 75% were classified with M1 disease. Only 59% of 3,527 men with prostate specific antigen 100 to 300 mg/ml had distant metastases on imaging. Five-year prostate cancer specific survival was 72% (95% CI 70-74) in men with prostate specific antigen 100 ng/ml or greater and MO, 24% (95% CI 23-25) in men with prostate specific antigen 100 ng/ml or greater and Ml, and 39% (95% CI 37-40) in men with prostate specific antigen less than 100 ng/ml and Ml. Conclusions: A fourth of men with prostate specific antigen 100 ng/ml or greater did not have distant metastases. They had twofold to threefold higher 5-year survival than men with distant metastases on imaging. Our findings strongly suggest that using prostate specific antigen 100 ng/ml or greater as an indicator of metastatic disease should be reconsidered.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a prostatic neoplasms
653 a adenocarcinoma
653 a prostate-specific antigen
653 a neoplasm metastasis
653 a Sweden
7001 a Sandin, Fredriku Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden.4 aut
7001 a Bratt, Olau Lund Univ, Dept Translat Med, Urol Canc Res Unit, Lund, Sweden.;Cambridge Hosp, Dept Urol, Cambridge, England.,Urological cancer, Malmö,Urologisk cancerforskning, Malmö4 aut
7001 a Lambe, Mu Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden.;Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden.,Department of Medical Epidemiology and Biostatistics (MEB)4 aut0 (Swepub:ki)6ff4c90e0827f27792e93a3b097d47a4
7102 a Uppsala universitetb Ortopedi4 org
7730 t Journal of Urologyd : Ovid Technologies (Wolters Kluwer Health)g 194:6, s. 1594-1600q 194:6<1594-1600x 0022-5347x 1527-3792
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-270951
8564 8u https://doi.org/10.1016/j.juro.2015.07.082
8564 8u oai:portal.research.lu.se:publications/62d7ecdb-8a6c-4dbd-8add-f2b34e1535f2
8564 8u https://ki.se/en/research/search-research-information?t=2&query=id%3A511909

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Stattin, Karl
Sandin, Fredrik
Bratt, Ola
Lambe, M
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Cancer och onkol ...
Artiklar i publikationen
Journal of Urolo ...
Av lärosätet
Uppsala universitet
Lunds universitet
Karolinska Institutet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst. Hantera kakor

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy